SynthesisJournal of cancer research and clinical oncology2023

Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis.

Maoyang Dou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.